-

ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

Article L233-8-II of the French Commercial Code
Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)

PARIS--(BUSINESS WIRE)--Regulatory News:

ABIONYX Pharma (Paris:ABNX):

Market: Euronext Paris, Compartment C
ISIN code: FR0012616852

Date

Number of shares outstanding

Total voting rights

Total gross (1)

Total net (2)

April 30, 2025

34,931,012

44,381,742

44,073,317

(1) The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

(2) The total number of net (or “exercisable at a Shareholders’ Meeting”) voting rights is calculated without taking into account shares for which voting rights have been suspended. It is released in order to ensure that the public is properly informed, in accordance with the recommendation made by the AMF on 17 July 2007.

About ABIONYX Pharma

ABIONYX Pharma is a next-generation biotech company focused on developing innovative medicines in diseases where there is no effective or existing treatment, even the rarest ones. The company expedites the development of novel therapeutics through an extensive expertise in lipid science and a differentiated apoA-I -based technology platform. ABIONYX Pharma is committed to radically improving treatment outcomes in sepsis and critical care.

Contacts

NewCap
Investor relations
Louis-Victor Delouvrier
abionyx@newcap.eu
+33 (0)1 44 71 98 53

NewCap
Media relations
Arthur Rouillé
abionyx@newcap.eu
+33 (0)1 44 71 00 15

ABIONYX Pharma

BOURSE:ABNX

Release Versions

Contacts

NewCap
Investor relations
Louis-Victor Delouvrier
abionyx@newcap.eu
+33 (0)1 44 71 98 53

NewCap
Media relations
Arthur Rouillé
abionyx@newcap.eu
+33 (0)1 44 71 00 15

More News From ABIONYX Pharma

ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

PARIS--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma (Paris:ABNX) Market: Euronext Paris, Compartment C ISIN code: FR0012616852 Date Number of shares outstanding Total voting rights Total gross (1) Total net (2) June 30, 2025 34,931,012 44,381,814 44,060,935 (1) The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shar...

ABIONYX Pharma: Half-Yearly Report on the Liquidity Contract With TP ICAP (Europe) SA

PARIS--(BUSINESS WIRE)--Regulatory News: Under the liquidity contract entered into by ABIONYX Pharma (Paris:ABNX) with TP ICAP (Europe) SA, the following assets were included in the liquidity account at June 30, 2025: Number of shares: 162,298 Cash balance: 86,279.52 € During the 1st half of 2025, a total of : PURCHASE 223,631 shares 275,707.78 € 253 transactions SALE 214,077 shares 272,643.70 € 226 transactions As a reminder, at the half-yearly balance sheet date of December 31, 2024, the foll...

ABIONYX Pharma Announces Approval of All Resolutions Put to the Vote at Its Combined General Meeting

TOULOUSE, France & LAKELAND, Mich.--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, announces that all resolutions presented at its Combined General Meeting were approved. ABIONYX Pharma would like to thank all shareholders present, represented or having voted by post for their commitment and support...
Back to Newsroom